Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Net Current Asset Value 2 year CAGR for the quarter ending January 31, 2024: -36.84%

Kalvista Pharmaceuticals Inc Net Current Asset Value 2 year CAGR is -36.84% for the quarter ending January 31, 2024, a -147.46% change year over year. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Net Current Asset Value for the quarter ending January 31, 2023 was 173,106,000.00, a -12.28% change year over year.
Kalvista Pharmaceuticals Inc Net Current Asset Value for the quarter ending January 31, 2022 was 197,348,000.00, a 259.71% change year over year.
Kalvista Pharmaceuticals Inc Net Current Asset Value for the quarter ending January 31, 2021 was 54,863,000.00, a -36.07% change year over year.
Kalvista Pharmaceuticals Inc Net Current Asset Value for the quarter ending January 31, 2020 was 85,817,000.00, a -15.51% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends